Lei Zheng, M.D., Ph.D. is an associate professor of Oncology and Surgery in the Gastrointestinal Oncology Program at the Johns Hopkins University School of Medicine and lead a large translational program that focuses on the preclinical and clinical development of novel vaccine- and antibody-based rational combination immunotherapy for gastrointestinal cancers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is Director of the Pancreatic Cancer Precision Medicine Program, a Pancreatic Cancer Center of Excellence program at Johns Hopkins and Leader of Personalized Medicine Program at the Bloomberg-Kimmel Institute for Cancer Immunotherapy. His clinical work is focused on multidisciplinary management for pancreatic cancer, bile duct cancer, liver metastases, and gastric cancer. In addition, he is a lead researcher in the group of Johns Hopkins Cancer Center’s physician scientists who have developed the pancreatic cancer GVAX vaccine and are currently leading eight investigator-initiated clinical trials of checkpoint inhibitor-based combination immunotherapy. More recently, his laboratory started to develop neoantigen-based vaccines and nanoparticle based adjuvant systems. He has also applied his knowledge gained from pancreatic cancer immune-based therapies to the development of a colorectal cancer vaccine and to the development of immunotherapy for bile duct cancer. He is affiliated with the Tumor Immunology Program as a laboratory investigator and possesses a large clinical trial associated biospecimen bank. His primary laboratory research focus is on the identification of new targets for pancreatic cancer therapies by dissecting tumor microenvironment of pancreatic cancer. Since 2013, he has published over 50 peer-reviewed papers and given more than 20 plenary and keynote speeches in national and international symposia. He is the founding Editor-in-Chief of Annals of Pancreatic Cancer, the only scientific journal that is solely focused on the malignant diseases of the pancreas. He is President of the Chinese American Hematologist and Oncologist Network (CAHON) and Secretary General of the Committee of Oversea Experts of the Chinese Society of Clinical Oncology (CSCO).